Advertisement
Screener

SCYNEXIS, Inc. (SCYX) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

1.5 / 5 stars · 27/92 Roast Me

SCYNEXIS, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

SCYNEXIS, Inc. (SCYX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 32.49 thousand shares for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-11-06.

Discontinued › Shareholders' Equity › Shares Granted or Issued, Share-Based Payment Arrangement

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2020-11-06

  • SCYNEXIS, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2020-09-30 was 9.73K shares, a 97.45% decline year-over-year.
  • SCYNEXIS, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2020-06-30 was -117.74K shares, a 255.91% decline year-over-year.
  • SCYNEXIS, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2020-03-31 was 140.50K shares, a 987.87% increase year-over-year.
  • SCYNEXIS, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2019-09-30 was 381.62K shares, a 956.73% increase year-over-year.
  • SCYNEXIS, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2017 was 220.00 shares, a 99.62% decline from fiscal 2016.
  • SCYNEXIS, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2016 was 58.26K shares, a 49.65% decline from fiscal 2015.
  • SCYNEXIS, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2015 was 115.71K shares, a 170.61% increase from fiscal 2014.
  • SCYNEXIS, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2014 was 42.76K shares.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month
2020-09-309.73K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06
-108.01K shares
derived: sum of 2 quarters · filed 2020-11-06
32.49K shares
10-Q · filed 2020-11-06
2020-06-30-117.74K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10
22.76K shares
10-Q · filed 2020-08-10
2020-03-31140.50K shares
10-Q · filed 2020-05-11
2019-09-30381.62K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12
457.14K shares
derived: sum of 2 quarters · filed 2019-11-12
470.05K shares
10-Q · filed 2019-11-12
2019-06-3075.52K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07
88.44K shares
10-Q · filed 2019-08-07
2019-03-3112.91K shares
10-Q · filed 2019-05-08
2018-09-3036.11K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13
149.09K shares
derived: sum of 2 quarters · filed 2018-11-13
183.82K shares
10-Q · filed 2018-11-13
183.82K shares
derived: sum of 4 quarters · filed 2018-11-13
2018-06-30112.98K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09
147.71K shares
10-Q · filed 2018-08-09
147.71K shares
derived: sum of 3 quarters · filed 2018-08-09
147.85K shares
derived: sum of 4 quarters · filed 2018-08-09
2018-03-3134.73K shares
10-Q · filed 2018-05-08
34.73K shares
derived: sum of 2 quarters · filed 2018-05-08
34.88K shares
derived: sum of 3 quarters · filed 2018-05-08
34.88K shares
derived: sum of 4 quarters · filed 2018-05-08
2017-12-310.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-13
147.00 shares
derived: sum of 2 quarters · filed 2018-03-13
147.00 shares
derived: sum of 3 quarters · filed 2018-03-13
220.00 shares
10-K · filed 2018-03-13
2017-09-30147.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07
147.00 shares
derived: sum of 2 quarters · filed 2017-11-07
220.00 shares
10-Q · filed 2017-11-07
2017-06-300.00 shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08
73.00 shares
10-Q · filed 2017-08-08
2017-03-3173.00 shares
10-Q · filed 2017-05-08
2016-12-3158.26K shares
10-K · filed 2018-03-13
2015-12-31115.71K shares
10-K · filed 2017-03-13
2014-12-3142.76K shares
10-K · filed 2016-03-07
2013-12-3127.97K shares
8-K · filed 2015-10-30

Similar stocks

Stock NameCountryMarket CapPE Ratio
PDS Biotechnology Corp (PDSB)United States$0.045B
Grace Therapeutics, Inc. (GRCE)$0.046B-1.83
VERU INC. (VERU)United States$0.043B-3.93
Werewolf Therapeutics, Inc. (HOWL)United States$0.047B
Kairos Pharma, LTD. (KAPA)United States$0.041B
Dogwood Therapeutics, Inc. (DWTX)United States$0.049B
Lite Strategy, Inc. (LITS)United States$0.049B
Incannex Healthcare Inc. (IXHL)$0.040B-22.32
Elicio Therapeutics, Inc. (ELTX)United States$0.049B
Karyopharm Therapeutics Inc. (KPTI)United States$0.039B-0.98